Market By Type, Industry Verticals, And Country | Forecast 2021-2028
As denoted in Triton Market Research’s report, the non-alcoholic steatohepatitis (NASH) biomarker market in the Middle East and Africa is foreseen to register growth based on value at a CAGR of 21.48% during the anticipated period 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries evaluated in this market are:
•       The United Arab Emirates
•       Turkey
•       South Africa
•       Saudi Arabia
•       Rest of Middle East & Africa
In Middle East and Africa, the studied market is expected to witness substantial growth, owing to the rise in the prevalence of NASH, enhancements in the healthcare sector, and an increase in awareness towards non-alcoholic steatohepatitis therapeutics. For instance, in Saudi Arabia, there is a tremendous surge in the number of NASH cases than non-alcoholic fatty liver diseases. Besides, the rise in obesity levels is adding to the occurrence of NASH cases across the country.
Further, obesity can directly lead to cardiovascular diseases, metabolic disorders, and even cancer. Here, as per statistics, a majority of the population is obese, resulting in higher deaths caused by obesity across Saudi Arabia. Thus, the growing number of obese and diabetic patients increases the emergence of NASH, which is estimated to contribute to developing the non-alcoholic steatohepatitis biomarker market in the upcoming years.
Furthermore, the reviewed market is estimated to gain traction in the UAE, owing to the rise in obesity, as well as type 2 diabetes mellitus. According to the National Institute of Health, the occurrence rate of non-alcoholic fatty liver disease is rising and is likely to surge rapidly until 2030. Along with this, the rise in the obesity rate has increased demand for various surgeries, such as bariatric surgery. Hence, the prevalence of such conditions holds the potential to drive the NASH biomarker market’s growth over the estimated period.
Pfizer Inc is a biopharmaceutical company involved in manufacturing and marketing products, such as vaccines, drugs, and consumer healthcare products. It provides its products for the treatment of respiratory, cardiovascular, and gastrointestinal diseases, among others. Pfizer has operations across various regions, including Middle East and Africa.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT
1. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1.  CONTRACTS & PARTNERSHIPS
2.6.2.  BUSINESS EXPANSIONS & DIVESTITURES
2.6.3.  ACQUISITIONS & MERGERS
2.6.4.  NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
2.7.2. INCREASING INCIDENCE RATE OF METABOLIC COMORBIDITIES
2.8. MARKET RESTRAINTS
2.8.1. SIDE-EFFECTS OF NASH THERAPEUTICS
2.8.2. UNAVAILABILITY OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
2.9. MARKET OPPORTUNITIES
2.9.1. GROWTH OPPORTUNITIES IN DEVELOPING REGIONS
2.9.2. RISE IN AWARENESS PERTAINING TO NON-ALCOHOLIC FATTY LIVER DISEASE
3. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY TYPE
3.1. SERUM BIOMARKER
3.2. HEPATIC FIBROSIS BIOMARKER
3.3. APOPTOSIS BIOMARKER
3.4. OXIDATIVE STRESS BIOMARKER
3.5. OTHER TYPES
4. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - BY INDUSTRY VERTICALS
4.1. PHARMA & CRO INDUSTRY
4.2. DIAGNOSTIC LAB
4.3. ACADEMIC RESEARCH KEY
4.4. HOSPITAL
5. MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - COUNTRY OUTLOOK
5.1. SAUDI ARABIA
5.2. UNITED ARAB EMIRATES
5.3. TURKEY
5.4. SOUTH AFRICA
5.5. REST OF MIDDLE EAST & AFRICA
6. COMPETITIVE LANDSCAPE
6.1. ALLERGAN
6.2. ASTRAZENECA
6.3. BRISTOL MYERS SQUIBB COMPANY
6.4. GENFIT SA
6.5. GILEAD SCIENCES INC
6.6. MADRIGAL PHARMACEUTICALS
6.7. MERCK & CO
6.8. NOVARTIS AG
6.9. NOVO NORDISK
6.10. PFIZER INC
6.11. SIEMENS HEALTHINEERS
6.12. VIKING THERAPEUTICS
6.13. ZYDUS CADILA
7. RESEARCH METHODOLOGY & SCOPE
7.1. RESEARCH SCOPE & DELIVERABLES
7.1.1. OBJECTIVES OF STUDY
7.1.2. SCOPE OF STUDY
7.2. SOURCES OF DATA
7.2.1. PRIMARY DATA SOURCES
7.2.2. SECONDARY DATA SOURCES
7.3. RESEARCH METHODOLOGY
7.3.1. EVALUATION OF PROPOSED MARKET
7.3.2. IDENTIFICATION OF DATA SOURCES
7.3.3. ASSESSMENT OF MARKET DETERMINANTS
7.3.4. DATA COLLECTION
7.3.5. DATA VALIDATION & ANALYSIS
TABLE 1:Â Â Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
TABLE 2:Â Â Â Â Â Â VENDOR LANDSCAPE
TABLE 3:Â Â Â Â Â Â LIST OF CONTRACTS & PARTNERSHIPS
TABLE 4:Â Â Â Â Â Â LIST OF BUSINESS EXPANSIONS & DIVESTITURES
TABLE 5:Â Â Â Â Â Â LIST OF ACQUISITIONS & MERGERS
TABLE 6:Â Â Â Â Â Â LIST OF NEW PRODUCT LAUNCHES
TABLE 7:Â Â Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2021-2028 (IN $ MILLION)
TABLE 8:Â Â Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2021-2028 (IN $ MILLION)
TABLE 9:Â Â Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2021-2028 (IN $ MILLION)
FIGURE 1:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 2:    PORTER’S FIVE FORCES ANALYSIS
FIGURE 3:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, 2020 & 2028 (IN %)
FIGURE 4:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 5:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 6:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 9:Â Â Â Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY INDUSTRY VERTICALS, 2020 & 2028 (IN %)
FIGURE 10:Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 11:Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 12:Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 13:Â MIDDLE EAST AND AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 14:Â SAUDI ARABIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 15:Â UNITED ARAB EMIRATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 16:Â TURKEY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 17:Â SOUTH AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)
FIGURE 18:Â REST OF MIDDLE EAST & AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET 2021-2028 (IN $ MILLION)